Moclobemide
Moclobemide structure
|
Common Name | Moclobemide | ||
|---|---|---|---|---|
| CAS Number | 71320-77-9 | Molecular Weight | 268.739 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 447.7±40.0 °C at 760 mmHg | |
| Molecular Formula | C13H17ClN2O2 | Melting Point | 137°C | |
| MSDS | Chinese USA | Flash Point | 224.6±27.3 °C | |
| Symbol |
GHS05, GHS07 |
Signal Word | Danger | |
|
Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.
Prog. Neuropsychopharmacol. Biol. Psychiatry 39(1) , 31-9, (2012) Monoamine oxidase (MAO) inhibitors were the first antidepressant drugs to be prescribed and are still used today with great success, especially in patients resistant to other antidepressants. In this study, we evaluated the MAO inhibitory properties and the p... |
|
|
[Serotonin syndrome in the course of drug-poisoning--case presentation].
Prz. Lek. 68(8) , 523-6, (2011) Serotonin syndrome is caused by excess serotonin in the central nervous system. It usually occurs as adverse drug-therapy (neuroleptic agents, monoamine oxidase inhibitors, serotonin reuptake inhibitors and others).a 50-year-old woman with a history of depres... |
|
|
[Obstructive sleep apnoea syndrome as the cause of atypical depression].
Fortschr. Neurol. Psychiatr. 79(9) , 531-4, (2011) Sleep apnoea is a common disorder presenting with somatic comorbidities and psychiatric symptoms. This case report describes a 43-year-old man with an organic depressive disorder due to obstructive sleep apnoea. Initially, an atypical depressive episode or sc... |
|
|
[The serotoninergic syndrome: moclobemide and citalopram].
Med. Clin. (Barc.) 113(17) , 677-8, (1999)
|
|
|
Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide.
J. Affect. Disord. 51(3) , 323-32, (1998) Chronic depression was once considered untreatable pharmacologically. Open studies conducted around 1980 demonstrated efficacious results with tricyclics, classical MAOIs and lithium in 45% of cases. The subsequent delineation of dysthymia in DSM-III and its ... |
|
|
Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation.
World J. Biol. Psychiatry 12(8) , 620-6, (2011) Previous publications demonstrated substitute benzamides as effective agents in treatment of clozapine-induced sialorrhea (CIS). The aim of this study was to compare efficacy of amisulpride and moclobemide (both from the substitute benzamide group) in control... |
|
|
Pharmacology of moclobemide.
Clin. Neuropharmacol. 16 Suppl 2 , S8-18, (1993) Moclobemide is a reversible inhibitor of monoamine oxidase (MAO) with clear preference for the A type (so-called RIMA). The enzyme inhibition shows complex kinetics, and the molecular mechanism of interaction with the enzyme is not yet clear. Moclobemide incr... |
|
|
Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture.
Naunyn Schmiedebergs Arch. Pharmacol. 382(5-6) , 409-17, (2010) An increasing body of evidence indicates that glial activation and neuroinflammation play an important role in the pathogenesis of psychiatric and neurodegenerative diseases. Activated glial cells secrete various cytokines that influence neurotransmission, hy... |
|
|
Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell.
J. Psychopharmacol. 27(1) , 98-108, (2013) Harmine is a β-carboline alkaloid and major component of ayahuasca, a traditional South American psychoactive tea with anecdotal efficacy for treatment of cocaine dependence. Harmine is an inhibitor of monoamine oxidase A (MAO-A) and interacts in vitro with s... |
|
|
Moclobemide treatment of clozapine-induced hypersalivation: pilot open study.
Clin. Neuropharmacol. 32(3) , 151-3, (2009) Clozapine-induced hypersalivation (CIHS) affects a mean of approximately 30% patients and is a troublesome adverse effect that leads to massive compliance problems in patients with schizophrenia. For the management of this distressing adverse effect, differen... |